High-Grade Glioma

The Ivy Brain Tumor Center at Barrow Neurological Institute, a nonprofit translational research program, is conducting a Phase 0/1 clinical trial to evaluate SILEVERTINIB (BDTX-1535), an experimental drug intended to block a key growth signal in patients with recurrent high-grade glioma and newly diagnosed glioblastoma, driven by EGFR (Epidermal Growth Factor Receptor) genetic aberrations.

The Gliofocus Study is a global, open-label, randomized Phase 3 clinical trial sponsored by the Ivy Brain Tumor Center that will compare the efficacy of niraparib, a PARP1/2-selective inhibitor, versus temozolomide in adult patients with newly diagnosed MGMT unmethylated glioblastoma. 

A Phase 0 research study of intravenous Aminolevulinic Acid Hydrochloride (ALA) and MR-guided focused ultrasound device (MRgFUS) in recurrent high-grade glioma patients.